|
US4197307A
(en)
|
1977-04-12 |
1980-04-08 |
Ciba-Geigy Corporation |
2-Alkylthio-, 2-alkylsulphinyl- and 2-alkylsulfonyl-6-phenylbenzimidazoles as anthelmintic agents
|
|
EP0377903A3
(de)
|
1989-01-09 |
1991-07-17 |
Bayer Ag |
Substituierte Hexahydro-1,2,4-triazindione, Verfahren zu ihrer Herstellung, Zwischenprodukte dafür und ihre Verwendung
|
|
EP1088819B1
(en)
|
1999-09-30 |
2005-06-15 |
Pfizer Products Inc. |
6-azauracil derivatives as thyroid receptor ligands
|
|
US6787652B1
(en)
*
|
1999-09-30 |
2004-09-07 |
Pfizer, Inc. |
6-Azauracil derivatives as thyroid receptor ligands
|
|
GB0015205D0
(en)
|
2000-06-21 |
2000-08-09 |
Karobio Ab |
Bioisosteric thyroid receptor ligands and method
|
|
WO2002051805A1
(de)
|
2000-12-27 |
2002-07-04 |
Bayer Aktiengesellschaft |
Indol-derivate
|
|
US7230031B2
(en)
|
2002-01-30 |
2007-06-12 |
Kissei Pharmaceutical Co., Ltd. |
Thyroid hormone receptor ligand, medicinal compositions containing the same and use thereof
|
|
WO2003094845A2
(en)
|
2002-05-08 |
2003-11-20 |
Bristol-Myers Squibb Company |
Pyridine-based thyroid receptor ligands
|
|
US7572799B2
(en)
|
2003-11-24 |
2009-08-11 |
Pfizer Inc |
Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
|
|
GB0327319D0
(en)
|
2003-11-24 |
2003-12-24 |
Pfizer Ltd |
Novel pharmaceuticals
|
|
FR2882750B1
(fr)
|
2005-03-03 |
2007-05-11 |
Pierre Fabre Medicament Sa |
Derives de 1,2,4-triazines, leur preparation et leur application en therapeutique humaine
|
|
GB0513692D0
(en)
*
|
2005-07-04 |
2005-08-10 |
Karobio Ab |
Novel pharmaceutical compositions
|
|
PL1919878T3
(pl)
|
2005-07-21 |
2011-03-31 |
Hoffmann La Roche |
Pochodne pirydazynonu jako agoniści receptora hormonu tarczycy
|
|
GB0608724D0
(en)
*
|
2006-05-03 |
2006-06-14 |
Karobio Ab |
Novel Pharmaceutical Compositions
|
|
WO2007132475A1
(en)
|
2006-05-15 |
2007-11-22 |
Cadila Healthcare Limited |
Selective tr-beta 1 agonist
|
|
GB0610322D0
(en)
*
|
2006-05-24 |
2006-07-05 |
Karobio Ab |
Novel pharmaceutical compositions
|
|
US8394811B2
(en)
|
2007-04-18 |
2013-03-12 |
Molsoft Llc |
Hydrazide compounds as thyroid hormone receptor modulators and uses thereof
|
|
WO2009001359A2
(en)
|
2007-06-27 |
2008-12-31 |
Quark Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of pro-apoptotic genes
|
|
TW200906823A
(en)
|
2007-07-16 |
2009-02-16 |
Lilly Co Eli |
Compounds and methods for modulating FXR
|
|
US8076334B2
(en)
*
|
2007-09-20 |
2011-12-13 |
Hoffmann-La Roche Inc. |
Prodrugs of thyroid hormone analogs
|
|
FR2933979B1
(fr)
|
2008-07-15 |
2012-08-24 |
Pf Medicament |
Derives de triazines et uraciles, leur preparation et leur application en therapeutique humaine
|
|
TWI534144B
(zh)
|
2009-04-20 |
2016-05-21 |
田邊三菱製藥股份有限公司 |
甲狀腺荷爾蒙β受體作動藥
|
|
WO2011038207A1
(en)
|
2009-09-25 |
2011-03-31 |
Metabasis Therapeutics, Inc. |
Phosphorus-containing thyroid hormone receptor agonists and methods of use
|
|
EP2780338B1
(en)
|
2011-11-14 |
2016-11-09 |
Ignyta, Inc. |
Uracil derivatives as axl and c-met kinase inhibitors
|
|
CN103130723B
(zh)
|
2011-11-30 |
2015-01-14 |
成都地奥制药集团有限公司 |
一种多聚(adp-核糖)聚合酶抑制剂
|
|
CN102898377B
(zh)
|
2012-02-14 |
2016-01-20 |
南京圣和药业股份有限公司 |
一类酞嗪酮衍生物及其用途
|
|
LT4406594T
(lt)
|
2012-09-17 |
2025-12-29 |
Madrigal Pharmaceuticals, Inc. |
Skydliaukės hormono analogai
|
|
BR112016023269A8
(pt)
|
2014-04-11 |
2021-06-29 |
Cymabay Therapeutics Inc |
uso de ácido (r)-2-(4-((2-etóxi-3-(4-(trifluormetil)fenóxi)propil)-tio)-2-metilfenóxi)-acético ou sal do mesmo na fabricação de um medicamento para tratar doença hepática gordurosa não alcoólica ou esteato-hepatite não alcoólica
|
|
EP3189046B1
(en)
|
2014-09-05 |
2020-08-26 |
Genentech, Inc. |
Therapeutic compounds and uses thereof
|
|
CN105477636B
(zh)
|
2015-10-16 |
2019-09-17 |
厦门大学 |
使用阿维菌素及其衍生物治疗代谢疾病的方法
|
|
TW202220968A
(zh)
|
2016-01-29 |
2022-06-01 |
美商維它藥物有限責任公司 |
ＲＯＲ－γ調節劑
|
|
JPWO2017170434A1
(ja)
|
2016-03-28 |
2019-01-31 |
インターセプト ファーマシューティカルズ， インコーポレイテッド |
Ｆｘｒアゴニストとａｒｂの組み合わせ医薬
|
|
HRP20250776T1
(hr)
|
2016-03-31 |
2025-08-29 |
Genfit |
Elafibranor za uporabu u liječenju primarnog bilijarnog kolangitisa
|
|
BR112018073460A2
(pt)
|
2016-05-25 |
2019-07-09 |
Akarna Therapeutics Ltd |
terapias combinadas usando moduladores do receptor farnesoide x (fxr)
|
|
WO2018027892A1
(en)
|
2016-08-12 |
2018-02-15 |
Eli Lilly And Company |
Amino pyrimidine ssao inhibitors
|
|
IL266054B2
(en)
*
|
2016-10-18 |
2023-10-01 |
Madrigal Pharmaceuticals Inc |
Methods for treating liver disorders or lipid disorders using a THR-BETA agonist
|
|
BR112019005930A2
(pt)
|
2016-10-19 |
2019-06-11 |
Boehringer Ingelheim Int |
combinações compreendendo um inibidor de ssao/vap-1 e um inibidor de sglt2, e usos das mesmas
|
|
WO2018103624A1
(zh)
|
2016-12-06 |
2018-06-14 |
江苏恒瑞医药股份有限公司 |
一种κ阿片受体激动剂在制备治疗法尼醇X受体激动剂引起的瘙痒的药物中的用途
|
|
KR20190117632A
(ko)
|
2017-02-21 |
2019-10-16 |
장피트 |
Ppar 효현제와 fxr 효현제의 병용
|
|
KR20190122806A
(ko)
|
2017-03-13 |
2019-10-30 |
장피트 |
조합 치료요법용 약학 조성물
|
|
US20200131129A1
(en)
|
2017-03-15 |
2020-04-30 |
Metacrine, Inc. |
Farnesoid x receptor agonists and uses thereof
|
|
CN110536682B
(zh)
|
2017-04-18 |
2023-01-06 |
基恩菲特公司 |
依拉非诺或其衍生物与抗nash、抗纤维化或抗胆汁淤积药剂的组合
|
|
WO2018208707A1
(en)
|
2017-05-08 |
2018-11-15 |
Neurovia, Inc. |
Methods and compositions for treating demyelinating diseases
|
|
US20210121493A1
(en)
|
2017-07-25 |
2021-04-29 |
Cedars-Sinai Medical Center |
Methods for treating liver diseases
|
|
JP2020531023A
(ja)
|
2017-08-25 |
2020-11-05 |
ジェンフィットＧｅｎｆｉｔ |
非アルコール性脂肪性肝疾患、非アルコール性脂肪性肝炎、及び／又は肝線維症の非侵襲的診断
|
|
WO2019053235A1
(en)
|
2017-09-15 |
2019-03-21 |
Genfit |
NON-INVASIVE DIAGNOSIS OF NON ALCOHOLIC LIVER DISEASES, NON ALCOHOLIC STHEATHEPATITIS AND / OR HEPATIC FIBROSIS
|
|
EA202090715A1
(ru)
|
2017-09-18 |
2020-07-15 |
Женфит |
Неинвазивная диагностика неалкогольных жировых дистрофий печени, неалкогольного стеатогепатита и/или фиброза печени
|
|
CN111511731B
(zh)
|
2017-11-01 |
2023-05-23 |
百时美施贵宝公司 |
作为法尼醇x受体调节剂的烯烃化合物
|
|
ES2986647T3
(es)
|
2017-11-13 |
2024-11-12 |
Gilead Sciences Inc |
Método de estadificación de la fibrosis hepática en pacientes con EHNA
|
|
CN109574995B
(zh)
*
|
2018-01-23 |
2020-07-24 |
深圳市塔吉瑞生物医药有限公司 |
取代的哒嗪酮化合物
|
|
CA3101274A1
(en)
|
2018-04-24 |
2019-10-31 |
Ph Pharma Co., Ltd. |
Use of neutrophil elastase inhibitors in liver disease
|
|
CN111801324B
(zh)
|
2018-06-12 |
2021-10-22 |
四川海思科制药有限公司 |
甲状腺激素受体激动剂及其用途
|
|
CA3110520A1
(en)
|
2018-08-24 |
2020-02-27 |
Terns, Inc. |
Thyroid hormone receptor beta agonist compounds
|
|
SG11202101863YA
(en)
|
2018-08-30 |
2021-03-30 |
Terns Pharmaceuticals Inc |
Treating liver disorders
|
|
IL281427B2
(en)
|
2018-09-18 |
2026-01-01 |
Terns Inc |
Compounds that inhibit tyrosine kinase activity for use in the treatment of leukemia
|
|
EA202190661A1
(ru)
|
2018-09-18 |
2021-08-13 |
Метакрайн, Инк. |
Агонисты фарнезоидного х-рецептора для лечения заболевания
|
|
TWI840423B
(zh)
|
2018-10-12 |
2024-05-01 |
美商拓臻股份有限公司 |
甲狀腺素受體β促效劑化合物
|
|
US12391677B2
(en)
|
2018-10-12 |
2025-08-19 |
InventisBio Co., Ltd. |
Thyroid hormone receptor agonists
|
|
CN111320609A
(zh)
|
2018-12-13 |
2020-06-23 |
拓臻股份有限公司 |
一种THRβ受体激动剂化合物及其制备方法和用途
|
|
WO2020131578A2
(en)
|
2018-12-17 |
2020-06-25 |
Mitopower Llc |
Nicotinyl riboside compounds and their uses
|
|
CN111484481A
(zh)
|
2019-01-26 |
2020-08-04 |
察略盛医药科技(上海)有限公司 |
哒嗪酮类衍生物、其制备方法及其在医药上的用途
|
|
US12338206B2
(en)
|
2019-02-21 |
2025-06-24 |
Nanjing Ruijie Pharma Co., Ltd. |
Compounds and their uses as thyroid hormone receptor agonists
|
|
GEP20247637B
(en)
|
2019-05-08 |
2024-06-25 |
Aligos Therapeutics Inc |
Modulators of thr-b and methods of use thereof
|
|
WO2020228577A1
(zh)
|
2019-05-10 |
2020-11-19 |
深圳微芯生物科技股份有限公司 |
一种哒嗪酮衍生物及其应用
|
|
CN114174282A
(zh)
|
2019-05-29 |
2022-03-11 |
南京明德新药研发有限公司 |
作为甲状腺素受体-β激动剂的哒嗪酮类衍生物及其应用
|
|
KR20220038368A
(ko)
|
2019-07-23 |
2022-03-28 |
노파르티스 아게 |
Fxr 작용제를 이용하는 간 질환의 병용 치료
|
|
CN112409340B
(zh)
|
2019-08-21 |
2022-03-18 |
海创药业股份有限公司 |
卤素取代的苯醚类化合物及其用途
|
|
AU2020336272A1
(en)
|
2019-08-23 |
2022-04-14 |
Terns Pharmaceuticals, Inc. |
Thyroid hormone receptor beta agonist compounds
|
|
CN114375193B
(zh)
|
2019-09-12 |
2024-05-14 |
拓臻制药公司 |
甲状腺激素受体β激动剂化合物
|
|
WO2021121210A1
(zh)
|
2019-12-16 |
2021-06-24 |
江苏恒瑞医药股份有限公司 |
并环类衍生物、其制备方法及其在医药上的应用
|
|
US20210379040A1
(en)
|
2020-05-13 |
2021-12-09 |
Terns Pharmaceuticals, Inc. |
Combination treatment of liver disorders
|
|
IL298144A
(en)
|
2020-05-13 |
2023-01-01 |
Terns Pharmaceuticals Inc |
Combination treatment of liver disorders
|
|
IL302099A
(en)
|
2020-10-15 |
2023-06-01 |
Lilly Co Eli |
Polymorphs of an fxr agonist
|
|
CN114437034A
(zh)
|
2020-11-06 |
2022-05-06 |
深圳微芯生物科技股份有限公司 |
一种酞嗪类化合物的可药用盐、晶型及其制备方法
|
|
JP2024502673A
(ja)
|
2021-01-14 |
2024-01-22 |
ウエヌイグレックオ・ファーマ |
Ｈｂｖ感染の処置のためのｆｘｒアゴニストとｉｆｎの相乗効果
|
|
CA3212130A1
(en)
|
2021-03-03 |
2022-09-09 |
Terns Pharmaceuticals, Inc. |
Thyroid hormone receptor beta agonist compounds
|
|
WO2022194278A1
(zh)
|
2021-03-19 |
2022-09-22 |
南京明德新药研发有限公司 |
双环苯酚类化合物及其应用
|
|
JP2024544538A
(ja)
|
2021-11-11 |
2024-12-03 |
ターンズ・ファーマシューティカルズ・インコーポレイテッド |
ＴＨＲ－βアゴニストによる肝障害の治療
|
|
TW202327589A
(zh)
|
2021-11-11 |
2023-07-16 |
美商拓臻製藥公司 |
肝病之組合療法
|
|
CA3238102A1
(en)
|
2021-11-11 |
2023-05-19 |
Terns Pharmaceuticals, Inc. |
Treating liver disorders with an ssao inhibitor
|
|
WO2023220404A1
(en)
|
2022-05-13 |
2023-11-16 |
Terns Pharmaceuticals, Inc. |
Treatment of non-alcoholic steatohepatitis
|
|
US20240398794A1
(en)
|
2023-04-07 |
2024-12-05 |
Terns Pharmaceuticals, Inc. |
COMBINATIONS OF GLP-1R AND THRß AGONISTS AND METHODS OF USE THEREOF
|